Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals reports 2025 financial results showing reduced net loss and $23 million cash post equity offerings. The FDA has recommended a second Phase 3 clinical trial for brilaroxazine in schizophrenia before NDA submission. The company plans to initiate the RECOVER-2 registrational trial mid-2026, supported by a comprehensive clinical …